Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-24 @ 10:54 PM
Ignite Modification Date: 2025-12-24 @ 10:54 PM
NCT ID: NCT05370469
Eligibility Criteria: Inclusion Criteria: * Provision of signed and dated informed consent form * Stated willingness to comply with all study procedures and availability for the duration of the study * Male or female, ≥18 years of age * Diagnosis of non-small cell lung cancer (NSCLC) with an actionable mutation * Currently prescribed oral tyrosine kinase inhibitors (TKIs). Participants may or may not have started taking the TKI prior to enrollment on this study. Participants who are initiating TKI treatment or are within 4 weeks of initiation of TKI treatment will be eligible for Cohort A. Participants who have been receiving TKIs for 4 or more weeks will be eligible for Cohort B. * Owns a smartphone or tablet * Ability and willingness to download and use a smart device application for the purposes of this study. Ability and willingness to use a Fitbit watch for the purposes of this study. * Must have the ability to access WiFi or a device with mobile network (3G, 4G, 5G, etc.) connectivity during the course of the study * Must be English speaking Exclusion Criteria: * Any physical or cognitive impairment that would prevent the subject from using the study devices or participate in the study procedures. * Any ongoing clinically significant grade ≥2 adverse events attributed to a previously prescribed TKI that is a different TKI from the one prescribed at enrollment for this study.
Healthy Volunteers: False
Sex: ALL
Minimum Age: 18 Years
Study: NCT05370469
Study Brief:
Protocol Section: NCT05370469